Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cymabay Therapeutics (NQ: CBAY )

19.71 +0.58 (+3.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,195,306
Open 19.03
Bid (Size) 19.35 (5)
Ask (Size) 19.85 (1)
Prev. Close 19.13
Today's Range 18.27 - 19.88
52wk Range 3.830 - 19.88
Shares Outstanding 84,677,939
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
Via Benzinga
Recap: CymaBay Therapeutics Q3 Earnings
Via Benzinga

Performance

YTD
+230.70%
+230.70%
1 Month
+20.48%
+20.48%
3 Month
+43.35%
+43.35%
6 Month
+134.36%
+134.36%
1 Year
+372.66%
+372.66%

More News

Read More
Earnings Outlook For CymaBay Therapeutics
Via Benzinga
Where CymaBay Therapeutics Stands With Analysts
Via Benzinga
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
Via The Motley Fool
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Via InvestorPlace
UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
Via Benzinga
Why CymaBay Therapeutics Stock Is Sinking This Week
Via The Motley Fool
Analyst Expectations for CymaBay Therapeutics's Future
Via Benzinga
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Climbs to New 52-Week High
Via Investor Brand Network
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Via Benzinga
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
Via The Motley Fool
Why CymaBay Therapeutics Stock Popped Again Today
Via The Motley Fool
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Earnings Preview For CymaBay Therapeutics
Via Benzinga
7 Analysts Have This to Say About CymaBay Therapeutics
Via Benzinga
Why CymaBay Therapeutics Stock Is Jumping Today
Via The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
Via Investor's Business Daily
Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
Via Benzinga
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
Via Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.